Péter Ágoston

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat et al. · The Lancet Oncology · 2019 · 503 citations · Full text

Medicine, Oncology, Radiation Oncology +13

Final Safety and Health-Related Quality of LIfe Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue Sarcoma

Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat et al. · International Journal of Radiation Oncology*Biology*Physics · 2022 · 44 citations · Full text

Medicine, Oncology, Radiation Oncology +15

Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial

Tibor Major, Csaba Polgár, Kliton Jorgo et al. · Brachytherapy · 2017 · 34 citations

Medicine, Radiation Oncology, Urology +16

Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study

Kliton Jorgo, Csaba Polgár, Tibor Major et al. · Pathology & Oncology Research · 2019 · 22 citations · Full text

Medicine, Oncology, Radiation Oncology +17

A phase II/III trial of hafnium oxide nanoparticles activated by radiotherapy in the treatment of locally advance soft tissue sarcoma of the extremity and trunk wall

S. Bonvalot, Piotr Rutkowski, Juliette Thariat et al. · Annals of Oncology · 2018 · 13 citations

Medicine, Oncology, Radiation Oncology +9